<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996515</url>
  </required_header>
  <id_info>
    <org_study_id>INST 0710C</org_study_id>
    <secondary_id>NCI-2011-02646</secondary_id>
    <nct_id>NCT00996515</nct_id>
  </id_info>
  <brief_title>A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies</brief_title>
  <official_title>A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Mexico Cancer Care Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Mexico Cancer Care Alliance</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To document the toxicities, and reversibility of toxicities, of this regimen of
      5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride).

      SECONDARY OBJECTIVES:

      I. To determine any potential anti-tumor effects, as determined by the objective tumor
      response (complete and partial responses), clinical benefit (complete and partial responses,
      and clinical benefit), the time to tumor response, the time to tumor progression, and the
      overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a dose-escalation study.

      Patients receive azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on
      days 1 and 15, days 1-2 and 15-16, days 1-3 and 15-17, or days 1-4 and 15-18. Patients also
      receive erlotinib hydrochloride orally (PO) daily on days 1-21. Courses repeat every 28 days
      in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 28 days and then every 3
      months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality and quantity of adverse events due to administration of erlotinib + 5-azacytidine, as therapy for the treatment of advanced or metastatic cancer.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Solid Tumor Malignancies</condition>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacytidine, erlotinib</intervention_name>
    <description>Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Erlotinib :- Tarceva™ (OSI-774)</other_name>
    <other_name>Vidaza (5-azacytidine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib PO and Vidaza IV</intervention_name>
    <description>Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must fulfill all of the following criteria to be eligible for study entry:

          -  Those who will be eligible will be all patients with non-hematologic neoplasms
             (lymphomas, leukemias, myeloma, myelodysplasia, or myeloproliferative syndromes) who
             have disease which has been previously treated and/or for which there is no acceptable
             standard treatment regimen available, and cannot be treated definitively with either
             surgery or radiotherapy. All will be appropriate candidates for treatment, and are not
             candidates for treatment with protocols of higher priority. All patients should have
             an ECOG/Zubrod/SWOG performance status of &lt;2 at the time of the initiation of therapy,
             adequate end-organ function, no severe comorbid disease, and ability to provide
             informed consent.

        Other Eligibility Criteria:

          -  Signed Informed Consent

          -  ECOG/Zubrod/SWOG Performance Status &lt;2 (Karnofsky Performance Status &gt; 70%)

          -  Life expectancy &gt; 8 weeks

          -  Male or female' age &gt;18 years

          -  Patients of childbearing potential must be using an effective means of contraception.

          -  Women of childbearing potential must have a negative serum pregnancy test prior to
             azacitidine treatment.

          -  Histologic diagnosis of a solid tumor malignancy that is advanced and cannot be
             treated adequately by radiotherapy or surgery; or metastatic disease

          -  Baseline laboratory values (bone marrow, renal, hepatic):

               -  Adequate bone marrow function:

               -  Absolute neutrophil count &gt;1000/µL

               -  Platelet count &gt;100'000/µL

               -  Renal function:

          -  Serum creatinine &lt; 1.5 x ULN

               -  Hepatic function:

          -  Bilirubin &lt;1.5x normal

               -  Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])
                  or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT])
                  levels &lt;=2 x ULN

               -  Serum calcium &lt; 12 mg/dl

        Exclusion Criteria:

        Patients meeting any of the following criteria are ineligible for study entry:

          -  Pregnant or lactating females

          -  Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0

          -  Uncontrolled' clinically significant dysrhythmia

          -  Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor
             growth in that lesion

          -  Uncontrolled metastatic disease of the central nervous system

          -  Sensitivity to erlotinib, 5-azacytidine or mannitol

          -  Advanced hepatic tumors

          -  Radiotherapy within the 2 weeks before Cycle 1' Day 1

          -  Surgery within the 2 weeks before Cycle 1' Day 1

          -  Any co morbid condition that' in the view of the attending physician' renders the
             patient at high risk from treatment complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie E Bauman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor Malignancies</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Vidaza</keyword>
  <keyword>Tarceva</keyword>
  <keyword>5-azacytidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

